Microangiopathic hemolytic anemia

Microangiopathic hemolytic anemia
Name	Microangiopathic hemolytic anemia
Field	Hematology
Symptoms	Fatigue, pallor, jaundice, petechiae, hematuria
Complications	Thrombosis, renal failure, neurologic deficits
Onset	Acute or subacute
Causes	Thrombotic microangiopathy, mechanical destruction
Diagnosis	Peripheral blood smear, schistocytes, ADAMTS13 activity
Treatment	Plasma exchange, immunosuppression, supportive care

Microangiopathic hemolytic anemia is a pattern of intravascular hemolysis caused by mechanical destruction of erythrocytes as they traverse damaged microvasculature. It presents with anemia, schistocytes on peripheral smear, and laboratory evidence of hemolysis and often occurs as part of thrombotic microangiopathies associated with diverse systemic conditions and iatrogenic exposures. Management targets the underlying process, frequently requiring urgent plasma exchange, immunotherapy, or removal of offending devices.

Signs and symptoms

Patients typically present with signs of anemia such as fatigue, pallor, and tachycardia alongside hemolytic features including jaundice, dark urine, and elevated bilirubin; these manifestations can accompany thrombocytopenia with petechiae and mucosal bleeding. In severe cases, multiorgan involvement yields renal impairment with oliguria or hematuria, neurologic deficits with confusion or focal signs, and fever; such systemic presentations may mirror crises reported in accounts of World War II campaigns and abrupt decompensations similar to events described in reports from Hurricane Katrina relief efforts. Physical findings may include splenomegaly, signs described in classic Harvey Cushing neurologic texts, or evidence of end-organ ischemia comparable to descriptions from the Great Chicago Fire historical record.

Causes and pathophysiology

Microangiopathic hemolytic anemia arises when erythrocytes are sheared by fibrin strands, platelet aggregates, or abnormal endothelial surfaces in small vessels. Major etiologies include thrombotic thrombocytopenic purpura (TTP) from severe ADAMTS13 deficiency often immune-mediated by autoantibodies, hemolytic uremic syndrome (HUS) classically associated with shiga-toxin-producing Escherichia coli outbreaks and complement-mediated atypical HUS with genetic variants in complement regulators. Additional causes include malignant hypertension as seen in accounts of Napoleon Bonaparte’s campaigns, systemic malignancies with tumor microemboli similar to thrombotic profiles in reports about Marie Curie’s radiology work, vascular graft hemolysis from mechanical prostheses reminiscent of innovations at institutions like Mayo Clinic, and disseminated intravascular coagulation in sepsis described in texts from Florence Nightingale era nursing. Pathophysiologic mechanisms overlap with complement activation, endothelial injury, platelet aggregation, and shear stress phenomena characterized in studies by researchers associated with Johns Hopkins Hospital and Massachusetts General Hospital.

Diagnosis

Diagnosis relies on peripheral blood smear demonstrating schistocytes, elevated lactate dehydrogenase, indirect hyperbilirubinemia, reduced haptoglobin, and reticulocytosis; thrombocytopenia commonly accompanies these findings. Specific testing includes ADAMTS13 activity assays and inhibitor testing to distinguish TTP from other thrombotic microangiopathies, complement genetic testing for atypical HUS, and shiga-toxin assays or stool cultures for enterohemorrhagic Escherichia coli outbreaks investigated by public health agencies like the Centers for Disease Control and Prevention. Imaging and organ-specific testing—creatinine for renal injury, neuroimaging when focal deficits occur—parallel diagnostic pathways used in evaluations at centers such as Cleveland Clinic and Johns Hopkins Hospital. History of recent chemotherapy, transplantation at institutions like Memorial Sloan Kettering Cancer Center, pregnancy complications including preeclampsia described in reports from Alexander Fleming era obstetrics, or exposure to prosthetic heart valves should be sought.

Differential diagnosis

Differential considerations include autoimmune hemolytic anemia mediated by warm or cold antibodies documented in case series from Royal Free Hospital; mechanical hemolysis from prosthetic valves as reported in cardiothoracic literature from Guy's Hospital; hereditary hemolytic disorders such as hereditary spherocytosis and sickle cell disease with foundational descriptions by clinicians at St Thomas' Hospital; paroxysmal nocturnal hemoglobinuria described in work from University College London; and severe infections or toxins producing hemolysis, akin to outbreaks cataloged by World Health Organization. Distinguishing features include direct antiglobulin test positivity in immune hemolysis, absence of schistocytes in some hereditary conditions, and ADAMTS13 levels for TTP assessment.

Management and treatment

Initial management emphasizes stabilization with transfusion support guided by protocols used at Royal Infirmary of Edinburgh and urgent plasma exchange for suspected TTP, which removes autoantibodies and replenishes ADAMTS13. Complement-mediated atypical HUS often requires complement inhibition with monoclonal antibodies targeting C5, therapeutic approaches developed through trials involving institutions like Karolinska Institutet and pharmaceutical partnerships documented in approvals by agencies such as the European Medicines Agency. Treatment of shiga-toxin HUS centers on supportive renal care, dialysis as practiced in renal units at Mount Sinai Hospital, and avoidance of antibiotics in certain settings per guidance from the Centers for Disease Control and Prevention. Management also addresses triggers: control of malignant hypertension per guidelines from American Heart Association, removal or replacement of hemolytic prosthetic devices in cardiac centers like Mayo Clinic, and treatment of underlying malignancy with protocols refined at Memorial Sloan Kettering Cancer Center.

Prognosis and complications

Prognosis varies by etiology and timeliness of treatment; untreated TTP historically had high mortality documented in early 20th-century case series, while plasma exchange and immunotherapy have markedly improved outcomes in modern cohorts reported by National Institutes of Health investigators. Complications include chronic renal impairment necessitating dialysis as described in nephrology reports from Karolinska Universitetssjukhuset, recurrent thrombotic events, neurologic sequelae with long-term disability noted in stroke registries at Massachusetts General Hospital, and treatment-related risks such as infections from immunosuppression tracked by infection control programs at Johns Hopkins Hospital. Long-term follow-up by multidisciplinary teams at centers like Cleveland Clinic is recommended to monitor for relapse and organ dysfunction.

Category:Blood disorders